Stocks · News reference
8-K filing — NovoCure Ltd (NVCR)
Filed: 2026-09-01 AccNo: 0001645113-26-000065 Size: 145 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- edgar
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.
Wedbush Maintains Neutral on NovoCure, Raises Price Target to $20
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and raises the price target from $18 to $20.